Akademik Veri Yönetim Sistemi
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.18, sa.1, 2012 (ESCI, TRDizin)
Objective: In this study, we aimed to investigate the seroprevalence of HBV and HCV in women admitted to Sanliurfa Obstetrics and Gynecology Hospital, to compare the results with the data previously reported from other regions of the country and to contribute to the nationwide epidemiological data. Materials and Methods: The prevalance of HBsAg, anti-HBs and anti-HCV ratios were retrospectively evaluated for pregnant and non pregnant women who admitted Sanliurfa Obstetrics and Gynecology Hospital between 1 January 2007 and 31 December 2009. Chemiluminescence immunoassay method (Vitros ECI Q, Ortho Clinical Diagnostics, U. S. A) was used for determination of all markers. Results: Total 56275 of women were pregnant, 6332 of women were not pregnant. At all of them, HbsAg was determined, whereas in 17351 of them antiHBs, and in 16858 of them anti-HCV was evaluated. In not pregnant women, the prevalance of HBsAg, anti-Hbs and anti-HCV were 4.8%, 44.9%, and 1.1%, respectively. In pregnant, the prevalance of HBsAg, anti-Hbs and anti-HCV were 3.5%, 25.0%, and 0.8%, respectively. In all women, HBsAg, anti-HBs and anti-HCV seropositivities were detected as 3.6%, 29.1% and 0.8% respectively. There was a significantly difference in HBsAg and anti-HBs seropositivity rates between age groups. However, detected anti-HCV rates by age groups, the difference was not stasitsically significant. Our seroprevalence results were compatible with the previously reported nationwide data. Conclusion: Implementation of effective screening and vaccination programmes particularly for women in reproductive age, pregnants and new borns would be suggested as appropriate measures in terms of public health.